142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

308024
How Meaningful Use Stage 3 can impact progress one Central Cancer Registry has made in Meaningful Use Stage 2

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 2:30 PM - 2:50 PM

Jeannette Jackson-Thompson, MSPH, PhD , Department of Health Management & Informatics/Missouri Cancer Registry & Research Center, University of Missouri School of Medicine, Columbia, MO
Iris Zachary, PhD, MSIT, CTR , Department of Health Management & Informatics, University of Missouri School of Medicine, Columbia, MO
BACKGROUND: In Missouri, many rural clinics and physician offices that under-report or do not report their cancer cases. When the Meaningful Use (MU) incentive program started it opened the door to increase cancer reporting from these rural locations. The Missouri Cancer Registry and Research Center (MCR-ARC), Missouri’s central cancer registry (CCR), was one of two CCRs funded to implement electronic health records (EHRs) reporting directly from a clinic/physician office (C/PO) into the CCR.

PURPOSE: MCR-ARC is looking at how MU Stage 3 will impact the cancer reporting criteria in Stage 2 as well as what factors will determine whether a C/PO will continue with MU past Stage 2.  The CCR also has to consider the possibility of social and behavioral history becoming a requirement and storage of this type of data in addition to the required data for cancer reporting.

METHODS: Working on a national workgroup to determine the impact MU Stage 3 will have on cancer reporting. Directly working with certified MU Stage 2 EHR/EMR vendors to analyze and assess any changes to cancer reporting because of Stage 3 requirements.

RESULTS: Final MU Stage 3 rules will not be completed until 2015. The 2015 Edition EHR Certification Criteria intended to improve upon would include any problems that need to be addressed from the 2014 edition, response to stakeholder feedback, and reference updated standards and implementation guides moving toward more interoperability.

DISCUSSION: Under MU Stage 2 Cancer Reporting was an option that providers could choose. With additional proposed requirements for MU Stage 3, this could enhance the cancer data to the point where social and behavioral factors may be used to determine cancer risk assessments. Cancer reporting currently collects Tobacco and Alcohol as well as Occupation and Industry if the information is available, MU Stage 3 will hopefully require it.

Learning Areas:

Communication and informatics
Other professions or practice related to public health
Public health or related organizational policy, standards, or other guidelines
Public health or related research

Learning Objectives:
Discuss the impact Meaningful Use Stage 3 has on EHR reporting to a cancer registry. List the effects Stage 3 will have on providers that report to the registry. Assess the steps the registry will need to take during the delay of Stage 3 to be ready when implemented.

Keyword(s): Data Collection and Surveillance, Public Health Research

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have graduate level degrees (MS-HI and PhD) in Health Informatics. I served as a Certified Tumor Registrar (CTR) and Assistant Database Administrator for the Missouri Cancer Registry and Research Center (MCR-ARC) before joining the faculty of the Department of Health Management & Informatics at the University of Missouri School of Medicine in 2013. My research interest include disease registries, electronic reporting and use of common data elements to improve public health surveillance and research.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.